BEAT BioTherapeutics Announces Scientific Presentation BEAT BioTherapeutics Corporation announced that co-founder and Scientific Advisory Board member Dr. Michael Regnier presented “AAV6-Mediated Cardiac-Specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility via Myosin Activation.” [Press release from BEAT BioTherapeutics (Business Wire) discussing research presented at the 19th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), Washington, DC] Press Release Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients Milo Biotechnology described promising safety and initial efficacy data in sporadic inclusion body myositis (sIBM) patients treated with follistatin gene therapy. In total, nine sIBM patients received follistatin gene therapy treatments and have been followed up to four years. [Press release from Milo Biotechnology discussing research presented at the 19th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), Washington, DC] Press Release Processed Fat Cells Show Potential as Treatment for Refractory Ischemia Patients Patients treated with processed autologous adipose-derived regenerative cells injected into the heart muscle demonstrated symptomatic improvement and a trend towards lower rates of heart failure hospitalizations and angina, despite no improvement in left ventricle ejection fraction or ventricular volumes. [Press release from the Society for Cardiovascular Angiography and Interventions (SCAI) discussing research presented at the SCAI 2016 Scientific Sessions, Orlando] Press Release Utah Study Finds Improvements in Warfarin Use for Atrial Fibrillation Treatment Necessary to Protect Kidney Function and Heart Health Atrial fibrillation patients taking Warfarin, a popular blood-thinning drug, are at higher risk of developing kidney failure if anticoagulation levels are not properly managed, according to a new study from researchers at the Intermountain Medical Center Heart Institute. [Press release from the Intermountain Medical Center Heart Institute discussing research presented at the Heart Rhythm Society’s 37th Annual Scientific Sessions, San Francisco] Press Release New Study Finds Patients with Atrial Fibrillation Who Are Treated with Common Blood Thinner Have Higher Rates of Dementia A new study by researchers at the Intermountain Medical Center Heart Institute of more than 10,000 patients treated long term with the blood thinner, Warfarin, revealed higher rates of dementia for patients with atrial fibrillation versus patients without the common heart rhythm disorder. [Press release from the Intermountain Medical Center Heart Institute discussing research presented at the Heart Rhythm Society’s 37th Annual Scientific Sessions, San Francisco] Press Release Study Finds Cardiac Ablation Doesn’t Reduce Atrial Fibrillation Risk for Patients with Syndrome Patients with Wolff-Parkinson-White syndrome who receive catheter ablation to cure their abnormal heart rhythms are just as likely as non-ablated patients to develop atrial fibrillation no matter what age they receive ablation, according to a new study. [Press release from the Intermountain Medical Center Heart Institute discussing research presented at the Heart Rhythm Society’s 37th Annual Scientific Sessions, San Francisco] Press Release New wallchart from our sponsor: Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy. |